Quantum Genomics

EU: ALQGC

€89.7m market cap

€5.32 last close

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Investment summary

Quantum Genomics is investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. The company recently released data from the Phase IIb NEW-HOPE trial, which strongly suggests that firibastat is an efficacious, safe drug. After eight weeks of treatment, patients saw a statistically significant reduction from baseline (p<0.0001) in systolic blood pressure of 9.7mmHg. A pivotal Phase III in resistant hypertension patients is expected to begin in H219. The company recently initiated their Phase IIb of firibastat in heart failure patients, with results expected in H220.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (10.3) (10.3) (93.45) N/A N/A
2018A 0.0 (13.6) (13.6) (93.94) N/A N/A
2019E 0.0 (16.8) (17.6) (88.49) N/A N/A
2020E 0.0 (20.9) (23.1) (111.62) N/A N/A
Last updated on 25/07/2019
Industry outlook

The angiotensin pathway is one of the primary methods of modulating blood pressure and is the target of many anti-hypertensive drugs, including ACE’s and ARB’s. However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by current drugs and that is being targeted by Quantum Genomics.

Last updated on 25/07/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 2.1
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 8.0 0.0 199.9
Relative* 6.4 (0.2) 195.4
52-week high/low €7.2/€1.7
*% relative to local index
Key management
Jean-Philippe Milon CEO
Marc Karako CFO
Lionel Ségard Founder & Chairman